Skip to main content

Table 3 Results of incremental economic analysis

From: Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

Treatment Mean Cost Mean QALYs Inc. Cost Inc. QALY ICER ICER v Conventional
At 10 years
Conventional management strategy £15,587 3.8 - - - -
Adalimumab £39,070 4.5 £23,484 0.7 Ext Dom’d £31,830
Golimumab £45,990 4.7 £6,920 0.2 Dom’d £33,178
Etanercept £44,701 4.8 £29,115 1.0 £28,917 £28,917
Infliximab £56,009 4.9 £11,308 0.1 £86,499 £35,534
At 40 years
Conventional management strategy £43,391 5.2 - - - -
Adalimumab £69,332 6.7 £25,941 1.5 Ext Dom’d £17,222
Golimumab £76,976 7.1 £7,629 0.4 Dom’d £17,435
Etanercept £75,563 7.2 £32,171 2.0 £16,426a £16,426
Infliximab £88,362 7.4 £12,799 0.2 £62,527b £20,789
  1. Dom’d, dominated (Treatment costs more and is less effective than the other intervention); Ext Dom’d, extendedly dominated (ICER is greater than that of the more effective intervention); ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years.
  2. aCompared with the next most effective strategy (excluding the extendedly dominated and dominated options) i.e. conventional management strategy. bCompared with the next most effective strategy (excluding the extendedly dominated and dominated options) i.e. etanercept.
\